Assessing your patient’s response to antiplatelet therapy should be easy.


 it is.


The VerfyNow System provides you with an easy, rapid and proven solution to assess your patient’s response to antiplatelet medications such as aspirin, clopidogrel, prasugel and GP IIb/IIIa inhibitors.

The VerifyNow System:

  • Helps assess patient’s response to all antiplatelet therapies
  • Provides results in less than 5 minutes*
  • Clinically validated in numerous peer-reviewed studies
  • Minimal hands-on time
  • Requires no pipetting or sample preparation, reducing the risk of pre-analytical error
  • Replaces more cumbersome and time consuming methods
  • Is reimbursable through CPT and ICD-9 codes

* additional sample incubation required, varies by test

For more information about the VerifyNow tests, please click

VerifyNow Aspirin Test (measures antiplatelet effect of aspirin) VerifyNow Aspirin Test

VerifyNow P2Y12 Test (measures antiplatelet effect of clopidogrel/Plavix® and prasugrel/Effient®) VerifyNow Aspirin Test

VerifyNow IIb/IIIa Test (measures antiplatelet effect of abciximab/ReoPro® and eptifibatide/Integrilin®) VerifyNow Aspirin Test

  • Dupont, AG. et al. Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. Thromb Res. 2009 May;124(1):6-13.
  • Patti, G. et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention. Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol. 2008; 52:1128–33.
  • Marcucci, R. et al. Cardiovascular death and nonfatal myocardial Infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay. A 12-Month follow-Up. Circulation. 2009;119(2):237-42.
  • Cuissett, T. et al. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardio;2008 Jun 15;101(12):1700-3.
  • Price, MJ. et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008 Apr;29(8):992-1000